denotes an abstract that is clinically relevant.
denotes that this is a ticketed session.
Description:
This session will focus on targeting therapies to improve response rates and outcomes in ALL across the age spectrum.
Professor Daniel DeAngelo will first review the different classes of monoclonal antibodies used in ALL. He will then go on to discuss CD20 antibodies, reviewing the role of rituximab; CD22 antibodies including epratuzumab and inotuzumab and finally CD19 antibodies which will include SGN19, an antibody-drug conjugate, and blinatumomab, a bi-specific T cell engager.
Professor Robin Foa will outline the precise diagnostic work-up of a BCR/ABL1+ ALL cases including work-up of the elderly and very elderly. He will illustrate how this allows treatment to be optimized and will discuss the TKI-based treatment strategies used. The differing response between p190 and p210 cases, the role of MRD monitoring and possible future chemo-free strategies will also be touched upon.
Professor Angela Thomas will discuss the potential in pediatric ALL to reduce toxicity and improve efficacy in resistant cases with more personalized and targeted therapies. She will also discuss how to introduce novel therapies into the pediatric population, allowing earlier access to such therapies as safely as possible.